Deep Genomics Closes $180 Million In Series C Funding

By Dan Anderson • Aug 6, 2021
  • Deep Genomics announced recently that they have closed a $180 million Series C financing round. These are the details.

Deep Genomics – a leading artificial intelligence (AI) therapeutics company – announced recently that they have closed a $180 million Series C financing round. SoftBank Vision Fund 2 led the financing with participation from new investors Canadian Pension Plan Investment Board (CPP Investments), Fidelity Management & Research Company LLC, Alexandria Venture Investments, and existing investors Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures.

Since being founded in 2015, Deep Genomics built a suite of predictive systems known as the AI Workbench – which has made billions of predictions across the entire human genome for millions of genetic variants, and hundreds of millions of novel compounds. And this level of productivity has not been possible using traditional non-AI approaches.

Deep Genomics has been rapidly progressing its first 10 AI-discovered programs toward the clinic. And the Series C funds will help the company expand the AI Workbench and scale its pipeline to 30 programs. The platform is increasingly being applied towards more complex and common diseases.

As part of this, the company is going to embark on a large-scale data generation effort across 100 genes to identify novel targets, mechanisms, and preclinical programs. And in addition, the company plans to advance four programs into the clinic by 2023 and further establish its clinical development capabilities. At the same time, Deep Genomics will continue to leverage partnerships with biopharmaceutical companies to expand its clinical development capacity.

Deep Genomics has utilized its strategic geographical advantage by combining its teams in Toronto, the birthplace of deep learning and the fastest growing technology hub in North America, with the Boston-Cambridge biotechnology hub, by hiring Jeffrey Brown, PhD, as VP of Preclinical Research, Ferdinand Massari, MD, as Chief Medical Officer, and Amanda Kay, PhD, as Chief Business Officer.

The company will continue to grow its footprint in Toronto, Ontario and Cambridge, Massachusetts, and expects to double its size in two years while building a culture that values a deep, shared understanding of AI, software engineering, and RNA biology.

In connection with the financing, Elena Viboch, Investment Director at SoftBank Investment Advisers, will join Deep Genomics’ Board of Directors.


“This financing further validates the significant advances in our AI discovery platform and growth of our proprietary preclinical pipeline. It is rewarding to work with investors who recognize the long-term potential of our AI platform as we continue to identify novel targets and develop transformative medicines for patients.”

“RNA therapeutics are a digital sequence of nucleotides, which means medicines have become digital information. Our AI Workbench enables us to precisely program RNA therapeutics, much like computer code, to perform a wide range of functions. This AI Workbench, paired with terabytes of proprietary data, enables us to tackle the enormous complexity of RNA biology and identify novel targets, mechanisms, and RNA therapeutics, which cannot be found without AI. We believe this will have a tremendous positive impact on patients’ lives.”

“The richness of our discovery environment has been built from the ground up based on cross-discipline collaboration. Our culture enables team members to become multilingual across AI, software engineering and biology.”

— Brendan Frey, PhD, FRSC, Founder & CEO of Deep Genomics

“The potential to identify novel targets and treat genetic diseases with programmable RNA therapeutics is one of the most significant opportunities in biotech. We believe Deep Genomics has built one of the most sophisticated and promising AI systems to create portfolios of novel medicines to treat genetic diseases. We are delighted to partner with Brendan and the Deep Genomics team to support their ambition of using AI to transform drug discovery.”

— Deep Nishar, Senior Managing Partner at SoftBank Investment Advisers